36 related articles for article (PubMed ID: 20712528)
21. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
[TBL] [Abstract][Full Text] [Related]
22. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer.
Narumiya K; Metzger R; Bollschweiler E; Alakus H; Brabender J; Drebber U; Hölscher AH; Warnecke-Eberz U
Pharmacogenomics; 2011 Feb; 12(2):205-14. PubMed ID: 21332314
[TBL] [Abstract][Full Text] [Related]
23. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
[TBL] [Abstract][Full Text] [Related]
24. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
26. CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancer.
Metzger R; Heukamp L; Drebber U; Bollschweiler E; Zander T; Hoelscher AH; Warnecke-Eberz U
Pharmacogenomics; 2010 Aug; 11(8):1105-13. PubMed ID: 20712528
[TBL] [Abstract][Full Text] [Related]
27. Predicting response to neoadjuvant therapy in esophageal cancer.
Vallböhmer D; Brabender J; Grimminger P; Schröder W; Hölscher AH
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1449-55. PubMed ID: 21929318
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers of response to preoperative chemoradiation in esophageal cancers.
Luthra R; Luthra MG; Izzo J; Wu TT; Lopez-Alvarez E; Malhotra U; Choi IS; Zhang L; Ajani JA
Semin Oncol; 2006 Dec; 33(6 Suppl 11):S2-5. PubMed ID: 17178277
[TBL] [Abstract][Full Text] [Related]
29. Predictive genetic markers in neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: a long way to go. Review of the literature.
Gusella M; Pezzolo E; Modena Y; Barile C; Menon D; Crepaldi G; La Russa F; Fraccon AP; Pasini F
Pharmacogenomics J; 2018 Jan; 18(1):14-22. PubMed ID: 28607505
[TBL] [Abstract][Full Text] [Related]
30. Current status of predictive biomarkers for neoadjuvant therapy in esophageal cancer.
Uemura N; Kondo T
World J Gastrointest Pathophysiol; 2014 Aug; 5(3):322-34. PubMed ID: 25133032
[TBL] [Abstract][Full Text] [Related]
31. Predictive factors for success of neo-adjuvant therapy in upper gastrointestinal cancer.
Walsh TN; Grannell M; Mansoor S
J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S172-5. PubMed ID: 12000603
[TBL] [Abstract][Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
